Hosni Ali, Huang Shao Hui, Goldstein David, Xu Wei, Chan Biu, Hansen Aaron, Weinreb Ilan, Bratman Scott V, Cho John, Giuliani Meredith, Hope Andrew, Kim John, O'Sullivan Brian, Waldron John, Ringash Jolie
Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada.
Department of Otolaryngology-Head & Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada.
Oral Oncol. 2016 Mar;54:75-80. doi: 10.1016/j.oraloncology.2015.11.023. Epub 2015 Dec 23.
To report outcomes of postoperative radiotherapy (PORT) for major salivary gland carcinoma (SGC) and identify patients at high risk of distant metastases (DM).
Patients with major SGC treated between 2000-2012 were identified. All patients underwent initial primary resection, with neck dissection (ND) therapeutically (if N+) or electively in high risk N0 patients. PORT was delivered using 3D-CRT or IMRT. Multivariable analysis (MVA) assessed predictors for DM, cause-specific (CSS) and overall survival.
Overall 304 patients were identified: 48% stage III-IVB, 22% lymphovascular invasion (LVI), 50% involved margins and 64% high risk pathology. ND was performed in 154 patients (51%). Adjuvant chemotherapy was used in 10 patients (3%). IMRT was delivered in 171 patients (56%) and 3D-CRT in 133 (44%). With a median follow-up of 82 months, the 5-(10-) year local, regional, distant control, CSS and OS were 96% (96%), 95% (94%), 80% (77%), 83% (82%) and 78% (75%), respectively. DM was the most frequent treatment failure (n=62). On MVA, stage III-IVB and LVI significantly correlated with DM, CSS and OS, while positive margins predicted DM and CSS, and high risk pathology predicted DM. No grade ⩾ 4 RTOG late toxicity was reported; 9 patients had grade 3, including osteoradionecrosis (n=4), neck fibrosis (n=3), trismus (n=1) and dysphagia (n=1).
Surgery and PORT with 3D-CRT/IMRT produced excellent long-term outcomes. Further research is required for patients with stage III-IVB, LVI, positive margins and high risk pathology to determine the incremental benefit of systemic therapy in management of SGC.
报告大涎腺癌(SGC)术后放疗(PORT)的结果,并确定远处转移(DM)高危患者。
确定2000年至2012年间接受治疗的大涎腺癌患者。所有患者均接受了初次原发灶切除,颈部清扫术(ND)用于治疗性清扫(如果N+)或选择性清扫高危N0患者。PORT采用三维适形放疗(3D-CRT)或调强放疗(IMRT)。多变量分析(MVA)评估DM、特定病因生存率(CSS)和总生存率的预测因素。
共确定304例患者:48%为III-IVB期,22%有脉管侵犯(LVI),50%切缘阳性,64%为高危病理类型。154例患者(51%)接受了颈部清扫术。10例患者(3%)使用了辅助化疗。171例患者(56%)接受了IMRT,133例患者(44%)接受了3D-CRT。中位随访82个月,5年(10年)局部、区域、远处控制率、CSS和总生存率分别为96%(96%)、95%(94%)、80%(77%)、83%(82%)和78%(75%)。DM是最常见的治疗失败原因(n=62)。在MVA中,III-IVB期和LVI与DM、CSS和总生存率显著相关,切缘阳性预测DM和CSS,高危病理类型预测DM。未报告≥4级美国放射肿瘤学会(RTOG)晚期毒性反应;9例患者出现3级毒性反应,包括放射性骨坏死(n=4)、颈部纤维化(n=3)、牙关紧闭(n=1)和吞咽困难(n=1)。
手术联合3D-CRT/IMRT的PORT产生了优异的长期疗效。对于III-IVB期、LVI、切缘阳性和高危病理类型的患者,需要进一步研究以确定全身治疗在SGC管理中的增量效益。